This article is more than 5 years old. Information may no longer be current.

Tyrogenex initiates phase 2 study of X-82 for wet AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Tyrogenex has initiated a phase 2 study of X-82 for the treatment of wet age-related macular degeneration, according to a press release.

The treatment is a dual inhibitor of VEGF and PDGF that is administered orally.

The randomized, double-masked, placebo-controlled, dose-finding APEX study will evaluate the safety and efficacy of X-82 in 132 subjects in the prevention of vision loss due to wet AMD.

The primary endpoint consists of mean change in visual acuity score throughout a 52-week follow-up and the reduction of the number of Eylea (aflibercept, Regeneron) injections needed during the study.

X-82 maintained or improved vision in all subjects during a 6-month phase 1 study. There were no dose-limiting toxicities, and rescue injections were not needed for most subjects.

“Current treatments for wet AMD require injections into the eye, and we believe an oral treatment, like X-82, may make a significant difference for patients who are battling blindness and for whom regular visits to the physician’s office are challenging,” Michael D. Webb, president and CEO of Tyrogenex, said in the release.